The author of 《Correction to Optimization of Fused Bicyclic Allosteric SHP2 Inhibitors [Erratum to document cited in CA170:599922]》 were Bagdanoff, Jeffrey T.; Chen, Zhouliang; Acker, Michael; Chen, Ying-Nan; Chan, Homan; Dore, Michael; Firestone, Brant; Fodor, Michelle; Fortanet, Jorge; Hentemann, Murphy; Kato, Mitsunori; Koenig, Robert; LaBonte, Laura R.; Liu, Shumei; Mohseni, Movarid; Ntaganda, Rukundo; Sarver, Patrick; Shultz, Michael D.; Smith, Troy; Sendzik, Martin; Stams, Travis; Spence, Stan; Towler, Christopher; Wang, Hongyun; Wang, Ping; Williams, Sarah L.; LaMarche, Matthew J.. And the article was published in Journal of Medicinal Chemistry in 2019. SDS of cas: 56602-33-6 The author mentioned the following in the article:
Michael D. Shultz should be listed as an addnl. coauthor; the order of the authors is listed in the byline.((1H-Benzo[d][1,2,3]triazol-1-yl)oxy)tris(dimethylamino)phosphonium hexafluorophosphate(V)(cas: 56602-33-6SDS of cas: 56602-33-6) was used in this study.
((1H-Benzo[d][1,2,3]triazol-1-yl)oxy)tris(dimethylamino)phosphonium hexafluorophosphate(V)(cas: 56602-33-6) is used as a reagent for peptide coupling, lactonization, selective esterification, amidation of alfa amino acids without racemization and synthesis of magnolamide for antioxidative activity and catalyst for 9-acridinecaroboxamide derivative. It acts as a substitute for (Benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (BOP) reagent.SDS of cas: 56602-33-6
Referemce:
1,2,3-Triazole – Wikipedia,
Triazoles – an overview | ScienceDirect Topics